Weihai Baihe Biology Technological Co., Ltd. (SHA:603102)
China · Delayed Price · Currency is CNY 44.56
-0.34 (-0.76%)
At close: Feb 13, 2026
SHA:603102 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 834.6 | 795.58 | 864.25 | 719.31 | 655.33 | 571.34 |
Other Revenue | 5.82 | 5.82 | 7 | 6.01 | 6.55 | 6.95 |
| 840.42 | 801.4 | 871.25 | 725.33 | 661.87 | 578.29 | |
Revenue Growth (YoY) | -0.55% | -8.02% | 20.12% | 9.59% | 14.45% | 15.74% |
Cost of Revenue | 554.47 | 512.02 | 550.89 | 466.93 | 390.4 | 328.58 |
Gross Profit | 285.95 | 289.38 | 320.36 | 258.4 | 271.48 | 249.71 |
Selling, General & Admin | 122.2 | 115.44 | 118.97 | 92.48 | 87.42 | 84.57 |
Research & Development | 40.64 | 35.78 | 30.95 | 22.51 | 24.06 | 20.74 |
Other Operating Expenses | 3.59 | 0.03 | -0.56 | 5.1 | 5.09 | 5.83 |
Operating Expenses | 166.86 | 152.52 | 149.49 | 120.19 | 117.51 | 112.05 |
Operating Income | 119.1 | 136.86 | 170.87 | 138.21 | 153.96 | 137.66 |
Interest Expense | -0.14 | -0.08 | -0.1 | -0.13 | -0.15 | - |
Interest & Investment Income | 15.64 | 14.75 | 15.5 | 8.91 | 1.71 | 1.51 |
Currency Exchange Gain (Loss) | 1.31 | 1.31 | 0.85 | 6.75 | -1.16 | -1.46 |
Other Non Operating Income (Expenses) | -2.1 | -0.2 | 0.09 | -0.37 | -0.2 | -0.3 |
EBT Excluding Unusual Items | 133.8 | 152.65 | 187.21 | 153.37 | 154.17 | 137.41 |
Gain (Loss) on Sale of Assets | 0.13 | 0.14 | 0.06 | 0.27 | -0 | - |
Asset Writedown | -4.12 | -0.01 | -0.34 | -0.04 | -0.65 | -0.34 |
Other Unusual Items | 11.07 | 8.1 | 6.49 | 4.63 | 15.81 | 10.94 |
Pretax Income | 140.88 | 160.88 | 193.42 | 158.22 | 169.33 | 148.02 |
Income Tax Expense | 19.28 | 21.57 | 24.36 | 20.38 | 21.29 | 20.9 |
Net Income | 121.6 | 139.31 | 169.07 | 137.84 | 148.04 | 127.12 |
Net Income to Common | 121.6 | 139.31 | 169.07 | 137.84 | 148.04 | 127.12 |
Net Income Growth | -22.56% | -17.60% | 22.65% | -6.89% | 16.46% | 71.00% |
Shares Outstanding (Basic) | 63 | 64 | 64 | 63 | 48 | 48 |
Shares Outstanding (Diluted) | 63 | 64 | 64 | 63 | 48 | 48 |
Shares Change (YoY) | -2.02% | -0.21% | 2.21% | 30.36% | 0.20% | 0.02% |
EPS (Basic) | 1.94 | 2.18 | 2.64 | 2.20 | 3.08 | 2.65 |
EPS (Diluted) | 1.94 | 2.18 | 2.64 | 2.20 | 3.08 | 2.65 |
EPS Growth | -20.97% | -17.42% | 20.00% | -28.57% | 16.23% | 70.97% |
Free Cash Flow | 98.04 | 32.73 | 97.33 | 101.36 | 44.6 | 116.03 |
Free Cash Flow Per Share | 1.56 | 0.51 | 1.52 | 1.62 | 0.93 | 2.42 |
Dividend Per Share | 0.750 | 0.750 | 0.750 | 0.600 | 0.500 | - |
Dividend Growth | - | - | 25.00% | 20.00% | - | - |
Gross Margin | 34.02% | 36.11% | 36.77% | 35.63% | 41.02% | 43.18% |
Operating Margin | 14.17% | 17.08% | 19.61% | 19.05% | 23.26% | 23.80% |
Profit Margin | 14.47% | 17.38% | 19.41% | 19.00% | 22.37% | 21.98% |
Free Cash Flow Margin | 11.67% | 4.08% | 11.17% | 13.98% | 6.74% | 20.06% |
EBITDA | 160.56 | 176.14 | 207.23 | 170.16 | 176.67 | 159.07 |
EBITDA Margin | 19.11% | 21.98% | 23.79% | 23.46% | 26.69% | 27.51% |
D&A For EBITDA | 41.47 | 39.28 | 36.36 | 31.95 | 22.71 | 21.41 |
EBIT | 119.1 | 136.86 | 170.87 | 138.21 | 153.96 | 137.66 |
EBIT Margin | 14.17% | 17.08% | 19.61% | 19.05% | 23.26% | 23.80% |
Effective Tax Rate | 13.68% | 13.41% | 12.59% | 12.88% | 12.57% | 14.12% |
Revenue as Reported | 840.42 | 801.4 | 871.25 | 725.33 | 661.87 | 578.29 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.